- Dr. Dave Singh, Vivos Therapeutics Inc. founder and Chief Medical Officer, releases his new book titled Pneumopedics and Craniofacial Epigenetics
- The book is the product of Dr. Singh’s years of research and is a chronology of Vivo Therapeutics’ strides in innovation
- The book mainly covers craniofacial growth and developmental Genetics
- It also highlights the relationship between dentofacial anomalies and developmental deficiencies associated with downstream conditions such as Obstructive Sleep Apnea (“OSA”)
Since its inception, Vivos Therapeutics (NASDAQ: VVOS) has been a trailblazer in diagnosing and treating mild-to-moderate Obstructive Sleep Apnea (“OSA”). Its main product — Vivos System — results from years of research and has been instrumental in treating the condition among adults. Dr. G. Dave Singh, the personality behind Vivos Therapeutics, shares the process behind Vivos System’s innovation and the scientific and biological foundation of the product in his new book titled Pneumopedics and Craniofacial Epigenetics. He details his research’s progress and Vivo Therapeutics’ achievements over the years.
Dr. Singh’s primary goal with this book is to spread the word far and wide about the technology, how it can help people think about health conditions such as OSA, and how such ailments are treated going forward. He covers craniofacial growth along with developmental Genetics. By doing so, he addresses the link between dentofacial anomalies and developmental deficiencies that are associated with downstream conditions including, but not limited to OSA. Dr. Singh also cements the scientific and biological foundation upon which Vivos Therapeutics’ proprietary approach rests. By so doing, he sheds more light on OSA while offering some incredible insights into the future of mild-to-moderate OSA diagnosis and treatment.
According to Vivos Life, over 80% of people who suffer from the effects of this condition do not know that they have it. Dr. Singh hopes that he will sensitize people about the disease with his new book, inform them both on how to identify it and how to treat it effectively. As a leading professor and researcher in the sleep medicine field, Dr. Singh understands the value of sharing knowledge and research. This book is a blend and an improvement on the over 200 peer-reviewed medical articles he has written throughout his career (https://ibn.fm/RVZsQ). It is also a way to share the strides that both he and Vivos Therapeutics Inc. have made regarding the treatment of mild-to-moderate OSA.
Vivos Therapeutics Inc.’s primary focus is developing and commercializing innovative diagnostic and treatment modalities for patients dealing with sleep-disordered breathing, including mild-to-moderate OSA. Its core mission is to rid the world of mild-to-moderate OSA, and the Vivos System is a significant clinical breakthrough on that front. Dr. Singh’s book is a chronicle of the process that ultimately led to the innovation of the Vivos System and how important the invention is to the treatment of OSA.
For more information, visit the company’s website at www.VivosLife.com.
NOTE TO INVESTORS: The latest news and updates relating to Vivos Therapeutics are available in the company’s newsroom at http://ibn.fm/VVOS
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
